Equities

Qingdao Vland Biotech INC

603739:SHH

Qingdao Vland Biotech INC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.22
  • Today's Change-0.26 / -2.48%
  • Shares traded3.68m
  • 1 Year change-27.31%
  • Beta1.0343
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.

  • Revenue in CNY (TTM)1.26bn
  • Net income in CNY78.59m
  • Incorporated2005
  • Employees1.57k
  • Location
    Qingdao Vland Biotech INCNo. 596-1Jiushui East Road, Laoshan DistrictQINGDAO 266100ChinaCHN
  • Phone+86 53 288978071
  • Fax+86 53 288966609
  • Websitehttp://www.vlandgroup.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xinjiang Bai Hua Cun Pharma Tech Co Ltd398.37m22.63m2.20bn787.0096.963.00--5.510.05930.05931.041.920.37281.481.87506,185.002.12-4.592.99-6.2447.9424.095.68-18.401.43--0.067--5.54-2.50137.33---21.00--
Qingdao Vland Biotech INC1.26bn78.59m2.65bn1.57k33.631.55--2.100.31160.31165.016.770.4323.494.07804,705.903.705.785.787.8945.4146.138.5710.340.868722.880.312733.593.078.0515.56-0.650724.68-6.89
Bide Pharmatech Co Ltd1.10bn77.60m2.72bn846.0034.511.38--2.470.86690.866912.2521.730.46871.024.831,301,939.003.26--3.73--38.92--6.96--5.04--0.043--30.94---24.94------
Shanghai Aladdin Biochemical Tech Co Ltd455.90m102.18m2.78bn566.0022.812.71--6.100.43970.43971.823.700.28660.35988.66805,473.806.798.837.819.6161.3461.4923.7026.853.13--0.272945.716.5519.36-7.489.9531.41--
Jiangsu Yahong Meditech Co Ltd94.17m-398.99m2.90bn394.00--1.32--30.81-0.6969-0.69690.16453.850.036611.125.92239,007.60-15.55-15.80-16.49-16.4877.8555.32-424.48-9,445.9110.12--0.0711--52,594.79---62.42--64.28--
Hinova Pharmaceuticals Inc109.74k-229.37m3.16bn179.00--2.47--28,818.65-2.32-2.320.001112.920.000077.250.0054613.07-14.92-31.86-16.50-37.18-400.96---209,012.60-25,578.247.21--0.036---100.00--2.44--124.37--
Shanghai Medicilon Inc1.01bn-269.57m3.34bn2.42k--1.37--3.29-2.01-2.017.6818.050.3656.191.32390,279.00-9.709.34-12.4911.731.8136.71-26.5714.932.87--0.092320.18-17.6833.26-109.82--23.60--
Beijing Kawin Technol Sha-hld Co Ltd1.44bn120.57m3.35bn584.0027.251.87--2.330.71920.71928.5610.480.62541.583.702,465,474.006.485.318.226.7683.0286.0210.368.103.22--0.10343.8221.7314.8739.7121.0425.01--
Beijing Sun-Novo Pharma Research Co Ltd1.03bn215.33m3.38bn1.39k15.683.10--3.271.921.929.239.730.591932.801.65754,698.2011.7312.9918.6521.7056.0653.9319.8221.341.9835.780.306510.7437.7647.2218.0854.9034.77--
HitGen Inc410.39m45.10m3.47bn452.0076.602.56--8.450.11290.11291.033.380.24187.225.05907,947.102.604.632.765.1049.2058.8910.7720.6616.5324.490.143119.1412.6419.6961.16-1.96-6.12--
Data as of Sep 13 2024. Currency figures normalised to Qingdao Vland Biotech INC's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.98%Per cent of shares held by top holders
HolderShares% Held
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20231.03m0.48%
Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023464.10k0.21%
China Asset Management Co., Ltd.as of 31 Dec 2023167.90k0.08%
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023138.18k0.06%
Manulife TEDA Fund Management Co., Ltd.as of 31 Dec 202382.50k0.04%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 202378.40k0.04%
China Southern Asset Management Co., Ltd.as of 31 Dec 202358.50k0.03%
CCB Principal Asset Management Co., Ltd.as of 29 Feb 202444.90k0.02%
China Fund Management Co., Ltd.as of 31 Dec 202331.00k0.01%
Bank of China Investment Management Co., Ltd.as of 31 Dec 202329.50k0.01%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.